Synthesis and anti-HIV evaluation of 2',3'-dideoxy imidazo- and ν- triazolo[4,5-d]pyridazine nucleosides

Bioorganic and Medicinal Chemistry

Volumn 7, Issue 11, 1999, Pages 2373-2379

  Bussolari, Jacqueline C ^a   Panzica, Raymond P ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

triazolopyridazines; ddI analogues; Deoxynucleosides; HIV; Imidazopyridazines

Indexed keywords

1 (2,3 DIDEOXY BETA DEXTRO GLYCEROPENTOFURANOSYL)IMIDAZO[4,5 D]PYRIDAZIN 4(5H) ONE; 1 (2,3 DIDEOXY BETA DEXTRO GLYCEROPENTOFURANOSYL)TRIAZOLO[4,5 D]PYRIDAZIN 4(5H) ONE; DIDANOSINE; IMIDAZOPYRIDAZINE DERIVATIVE; NUCLEOSIDE DERIVATIVE; TRIAZOLOPYRIDAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; OXYGENATION;

ANTI-HIV AGENTS; CELLS, CULTURED; DIDANOSINE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033490797     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(99)00184-4     Document Type: Article

References (24)

1. Mitsuya H., Yarchoan R., Broder S. Science. 249:1990;1533.
2. Huryn D.M., Okabe M. Chem. Rev. 92:1992;1745.
3. De Clercq E. Nucleosides Nucleotides. 13:1994;1271.
4. De Clercq E. J. Med. Chem. 38:1995;2491.
5. Mansour T.S., Storer R. Current Pharmac. Design. 3:1997;227.
6. Karkala, R.; Panzica, R. P. J. Chem. Soc., Perkin Trans. 1 1989, 1769.
7. Bussolari J.C., Karkala R., Stoeckler J.D., Chen S.-F., Panzica R.P. J. Med. Chem. 36:1993;4113.
8. Bussolari J.C., Stoeckler J.D., Panzica R.P. Bioorg. Med. Chem. 4:1996;1725.
9. Seela F., Rosemeyer H., Gumbiowski R., Mersmann K., Muth H.-P., Roling A. Nucleosides Nucleotides. 10:1991;409.
10. Seela F., Muth H.-P., Roling A. Helv. Chim. Acta. 74:1991;554.
11. Seela F., Mersmann K. Helv. Chim. Acta. 75:1992;1885.
12. Balzarini J., Baba M., Pauweis R., Herdewijn P., Robins M.J., DeClercq E. Mol. Pharm. 33:1988;249.
13. Ahluwalia G., Cooney D.A., Mitsuya H., Fridland A., Flora K.P., Hao Z., Dalal M., Broder S., Johns D.G. Biochem. Pharmac. 36:1987;3797.
14. On larger scale reactions (e.g. 5-10 g of 3) the average yield of 4/5 was 80%.
15. + neutralization of the reaction solution led to a small amount of the α-anomer. Although efforts to prevent anomerization were made, the occurrence of the α-anomer was always detected. Personal communication from Dr. Jean-Luc Girardet. For the mechanism of anomerization see, Capon B. Chem. Rev. 1969, 69, 407.
16. Barton, D. H. R.; Subramanian, R. J. Chem. Soc. Perkin Trans. 1 1977, 1718.
17. Gosselin G., Mathe C., Bergogne M.-C., Aubertin A.-M., Kirn A., Sommadossi J.-P., Schinazi R., Imbach J.-L. Nucleosides Nucleotides. 14:1995;611.
18. Jang, D. O., Cho, D. H., Barton, D. H. R. Synlett 1998, 39
19. Dimock S., Bhat B., Peoc'h D., Sanghvi Y.S., Swayze E.E. Nucleosides Nucleotides. 16:1997;1629.
20. Weislow O.W., Kiser R., Fine D., Bader J., Shoemaker R.H., Boyd M.R. J. Natl. Cancer Inst. 81:1989;577.
21. Racha S., Vargeese C., Vemishetti P., El-Subbagh H.I., Abushanab E., Panzica R.P. J. Med. Chem. 39:1996;1130.
22. Berkowitz D.B., Eggen M., Shen Q., Sloss D.G. J. Org. Chem. 58:1993;6174.
23. Matulic-Adamic J., Haeberli P., Usman N. J. Org. Chem. 60:1995;2563.
24. Reist, E. J.; Sturm, P. A.; Pong, R. Y.; Tanga, M. J.; Sidwell, R. W. In Nucleotide Analogues as Antiviral Agents: Martin, J. C., Ed.; American Chemical Society: Washington (DC), 1989: pp 17-34.